NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Carmine Therapeutics

Carmine Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.carminetherapeutics.com/

Last Round

Series A

Oct 13, 2022

Total Funding Raised

$22.1M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Carmine Therapeutics is a biotechnology company that develops non-viral gene therapies using its proprietary red blood cell extracellular vesicle (RBCEV) platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyextracellular vesiclesnon-viral deliveryRBCEVdrug delivery platformbiotech R&Dgenetic medicinebiotech licensingtherapeutic payloadexosome therapygene deliverybiotech partnership

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Carmine Therapeutics Comparables

Compare Carmine Therapeutics with similar companies based on industry and business-model similarity.

Carmine Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
STRM.BIO
88%
Anjarium Biosciences
87%
Vesigen Therapeutics
87%

Carmine Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 13, 2022
Convertible DebtJun 30, 2020
SeedAug 28, 2019

Key People

Founding team and executive leadership

XiangQian XQ Lin

Chairman And Founder (former Founding CEO)

Founding Team

Carmine Therapeutics Investors

Notable investors and investment history

Carmine Therapeutics investors
InvestorRounds
Cystic Fibrosis FoundationSeries A
Huagai CapitalSeries A
EVX VenturesSeries A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2026

    Monthly visitors grew 98% MoM.

  • Apr 19, 2026

    Monthly visitors grew 59% MoM.

Carmine Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Carmine Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Carmine Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range6
Year Founded2019
Last FundingOct 13, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.